From “Undruggable” to Attainable: Genesis Therapeutics’ AI Journey Bolstered by US$200 Million Series B Funding
Genesis Therapeutics, an artificial intelligence (AI)-focused company in the pharmaceutical sector based in Burlingame, California, has raised US$200 million in a successful Series B funding round.
Genesis Therapeutics, an artificial intelligence (AI)-focused company in the pharmaceutical sector based in Burlingame, California, has raised US$200 million in a successful Series B funding round.